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Abstract  We report a case of a 42-year-old female with Arrhythmogenic Right Ventricular Cardiomyopathy 
(ARVC) who presented with recurrent episodes of palpitations, dizziness and lightheadedness. On evaluation, she 
developed a new onset sustained ventricular tachycardia (VT) and the diagnosis was confirmed through genetic 
testing, cardiac imaging, and electrophysiological study. Insertion of automatic implantable cardioverter defibrillator 
(AICD), antiarrhythmic medication, and ventricular ectopy radiofrequency ablation afforded improvement of 
symptoms. In conclusion, combination of these treatment modalities abated ventricular tachycardia from ARVC. 
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1. Introduction 
Arrhythmogenic Right Ventricular Cardiomyopathy 
may present with symptomatic sustained ventricular 
tachycardia which may be fatal that could lead to sudden 
cardiac death. This would mean early specialized 
intervention to abate symptoms and most importantly to 
prevent life threatening arrhythmias that could progress to 
cardiac arrest. 
2. Case Presentation 
A 42-year-old female diagnosed with ARVC at the age 
of 36 when she presented with recurrent episodes of 
palpitations, dizziness and lightheadedness. The diagnosis 
was confirmed by genetic testing though with an 
unspecified genomic information, electrocardiography, 
cardiac imaging, and electrophysiological study. No 
history of the same disease or sudden cardiac death in the 
family though his father has had atrial fibrillation. Six 
years ago, she gradually experienced intermittent episodes 
of palpitations which progressed to recurrent attacks of 
lightheadedness and dizziness. She denied chest pain, 
dyspnea or orthopnea during this time. Though her initial 
electrocardiogram showed normal sinus rhythm with 
normal axis and first degree atrioventricular block, her 
inpatient telemetry captured several runs of sustained 
monomorphic ventricular tachycardia (Figure 1). 
Transthoracic echocardiogram revealed normal left atrium, 
left ventricular cavity size and wall thickness with mildly 
reduced systolic function with an estimated ejection 
fraction of 40% and note of regional wall motion 
abnormalities. Cardiac catheterization showed normal 
coronary arteries, severe left ventricular dysfunction and 
elevated ventricular end diastolic pressure. Cardiac 
magnetic resonance imaging was highly suspicious of 
AVRC. Electrophysiology study demonstrated new 
morphology of inducible monomorphic VT, confirming 
that she did not have a single morphology thus more 
suggestive of arrhythmogenic right ventricular 
cardiomyopathy. She was initiated on sotalol and 
mexiletene and eventually had an AICD inserted. 
Throughout the years, she had several hospital admissions 
due to palpitations, dizziness, lightheadedness, and 
defibrillator firing. Her AICD has been interrogated as 
well as her antiarrhythmic medications have been 
cautiously adjusted which afforded improvement on her 
symptoms and diminished discharge of her cardiac device. 
Her recent hospital admission was due to palpitations 
and intracardiac device firing which she felt. She denied 
chest pain however she had mild dizziness and 
lightheadedness. She was noted to have sustained VT 
(Figure 2). Her blood pressure has been within the range 
during this course. She was started on amiodarone and 
lidocaine drips which converted her ectopy to sinus 
rhythm (Figure 3). Due to the intermittent episodes of 
sustained VT despite antiarrhythmic medications and 
intracardiac device, radiofrequency catheter ablation of 
the ventricular ectopy was recommended. The procedure 
was done successfully with no recurrence of palpitations, 
dizziness, lightheadedness, and device firing to date. 
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Figure 1. Patient`s Telemetry Rhythm during her first hospitalization six years ago. The tracing revealed ventricular tachycardia with paced rhythm 
 
Figure 2. Patient`s 12 Lead Electrocardiogram when she presented with palpitations and cardiac device firing on her latest hospital admission this year. 
The tracing revealed sustained ventricular tachycardia 
 
Figure 3. Patient`s 12 Lead Electrocardiogram after the initiation of amiodarone and lidocaine drips. The tracing revealed normal sinus rhythm, left axis 
deviation 
3. Discussion 
ARVC is an inherited myocardial disease which 
predominantly affects the right ventricle (RV) and is 
characterized pathologically by gradual replacement of 
myocytes by fibrous tissue that can result in arrhythmia, 
sudden cardiac death (SCD), and heart failure. 
ARVC was first described in 1977 in a report of six 
patients with sustained VT and enlarged RV [1]. It is most 
commonly inherited as an autosomal dominant trait with 
variable penetrance ranging from 20-25% of family 
members [2,3], with the first chromosomal locus 
identified at 14q23-q24 after clinical evaluation of a large 
Italian family [4]. An autosomal recessive variant (also 
called Naxos Disease) has been described in which there 
is a cosegregation of cardiac (ARVC), skin (palmoplantar 
keratosis), and hair (woolly hair) abnormalities and has 
been mapped on chromosome 17 (locus 17q21) [5]. The 
etiology of this malignant form was found to be a two -
base pair deletion in the gene encoding the desmosomal 
protein plakoglobin [6], a major component of cell 
adhesion junction. This stimulated research for the 
elucidation of desmoplakin gene which has been 
associated with the more common autosomal form [7]. 
Diminished level of plakoglobin showed a 91% sensitivity, 
82% specificity, 83% positive predictive value and 90% 
negative predictive value, implying that a reduced 
immuno reactive signal of plakoglobin at the intercalated 
disk is a consistent feature in patients with ARVC [8]. 
Sixty eight percent of myocardial samples with 
histomorphologic manifestations of ARVC displayed 
decreased plakoglobin staining which might serve as an 
additional diagnostic marker of ARVC in forensic 
pathology [9]. 
The prevalence of the disease is estimated to affect 1 in 
1000-5000 population and is more common in individuals 
of Greek and Italian origin [10]. In the United States, the 
median age at presentation was 26 years (51% were 
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males), the median time to diagnosis was one year from 
the initial presentation, and the median survival was 60 
years [11]. 
The diagnosis of the disease is estabished on the 
proposed standardized criteria based upon the identification 
of structural, histological, electrocardiographic, arrhythmic, 
and familial features, which were further subclassified into 
major and minor criteria [12] that would categorize it 
further into definite, borderline or possible diagnosis. 
Biomarkers have been studied including 1.64 fold rise in 
heat shock protein 70 (HSP70) in ARVC failing hearts 
compared with non-failing hearts [13], phasic elevation of 
troponin I with normal coronary angiogram in an ARVC 
patient who presented with symptomatic VT terminated 
by ICD discharges [14], and a recently proposed early 
biomarker MiR-320 which is significantly down-regulated 
in ARVC patient’s plasma [15]. 
A large series at a tertiary referral center reported the 
frequency of the principle symptoms associated with 
ARVC as follows: palpitations (67%), syncope (32%), 
atypical chest pain (27%), dyspnea (11%), and right 
ventricular failure (6%) [16]. Patients typically present 
with palpitations or syncope as the manifestation of 
ventricular arrhythmias which can range from frequent 
ventricular premature beats to sustained VT [11]. Sustained 
or nonsustained monomorphic VT is the most common 
ventricular arrhythmia and it originates in the RV and 
therefore has a left bundle branch block (LBBB) pattern 
[11,17]. 
SCD exist in patients with ARVC and can be its initial 
presentation [11,17,18,19]. A forensic autopsy review for 
SCD revealed 10.4% was associated with ARVC with 
75% occurred during routine daily activities, 10% percent 
during the perioperative period, and 3.5% while 
participating in sports [20]. 
An indispensable initial approach is to obtain a 12-lead 
electrocardiogram (ECG) and transthoracic echocardiography 
in all patients with a suspected diagnosis of ARVC. 
Additional testing had been recommended based on the 
clinical scenario or when the results of initial testing are 
non-diagnostic and may include one or more of the 
following: signal-averaged ECG (SAECG), 24-hour ECG 
monitoring, exercise ECG testing, cardiac magnetic 
resonance imaging, right ventriculography, endomyocardial 
biopsy, electrophysiological study, and genetic testing 
[21]. 
The presence of arrhythmia (nonsustained ventricular 
tachycardia, VT or frequent and complex premature 
ventricular contractions) or symptoms would entail 
treatment initiation with beta-blockers or implantable 
cardioverter-defibrillator (ICD) with additional medical 
therapy to prevent defibrillator discharge [22]. Sotalol 
prevented VT during programmed ventricular stimulation 
in 68% of the patients, whereas class Ia and Ib drugs were 
effective in only 5.6% and class Ic drugs in only 2% of 
patients [23]. 
The 2006 ACC/AHA/ESC guidelines for the management 
of ventricular arrhythmias and SCD recommended that 
sotalol or amiodarone may be effective therapies for the 
treatment of sustained VT or VF in patients with ARVC in 
whom ICD implantation is not feasible [24]. Radiofrequency 
ablation is not a definitive therapy due to the variable and 
progressive nature of ARVC however successful treatment 
of some of the arrhythmogenic foci can be effected by it 
[25,26,27]. 
Both the 2006 ACC/AHA/ESC guidelines for the 
management of ventricular arrhythmias and the prevention 
of SCD and the 2012 ACCF/AHA/HRS guidelines on 
device-based therapy for cardiac rhythm abnormalities 
agreed that an ICD should be implanted in patients with 
ARVC and documented sustained VT or VF for the 
primary prevention of SCD [24,28]. 
A meta-analysis of AVRC patients with ICD for either 
primary or secondary prevention determined an annual 
rate of cardiac death, noncardiac death, and heart 
transplantation as 0.9 percent, 0.8 percent, and 0.9 percent 
respectively [29]. Most of the AVRC patients appear to do 
relatively well though they do carry a risk of developing 
heart failure and ventricular arrhythmias. 
4. Conclusion 
Arrhythmogenic right ventricular cardiomyopathy is 
progressively regarded as an etiology of malignant 
ventricular arrhythmias especially among healthy young 
adults and in those individuals hooked to vigorous 
exercise. It should be taken into account by physicians in 
young patients with cardiac arrhythmias or unexplored 
cardiomyopathy. Treatment involves the abolishment of 
malignant arrhythmias with antiarrhythmic agents, but 
now, is geared towards automatic implantable defibrillator 
placement as the most effective modality to arrest sudden 
cardiac death. 
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